Medicare Alzheimer’s Coverage Policy Advancing Clinical Trial Diversity Efforts
Executive Summary
Medicare national coverage determination for Alzheimer’s drugs has been a ‘game changer’ in terms of motivating industry to boost diversity in clinical studies in the disease, trial expert says.
You may also be interested in...
Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads
Donanemab’s review delay will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research. The company has also been supporting development of blood-based tools for early diagnoses, though they would not eliminate PET scans.
Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads
Lilly is supporting development of blood-based tools for early diagnose of Alzheimer's, but the delay of the review for donanemab will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research.
Payers, Medical Journals Could Help Push For Clinical Trial Diversity, Cavazzoni Says
The director of the US FDA’s Center for Drug Evaluation and Research acknowledged that the FDA cannot improve trial diversity alone.